CNS Pharmaceuticals (CNSP) Competitors $7.70 -0.28 (-3.51%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$8.04 +0.34 (+4.35%) As of 08/1/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. NEUP, MTEX, ALLR, LPTX, NERV, EQ, ERNA, BFRG, ALVR, and BIVIShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Neuphoria Therapeutics (NEUP), Mannatech (MTEX), Allarity Therapeutics (ALLR), Leap Therapeutics (LPTX), Minerva Neurosciences (NERV), Equillium (EQ), Ernexa Therapeutics (ERNA), Bullfrog AI (BFRG), AlloVir (ALVR), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Neuphoria Therapeutics Mannatech Allarity Therapeutics Leap Therapeutics Minerva Neurosciences Equillium Ernexa Therapeutics Bullfrog AI AlloVir BioVie CNS Pharmaceuticals (NASDAQ:CNSP) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, CNSP or NEUP? CNS Pharmaceuticals has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Does the media refer more to CNSP or NEUP? In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score. Company Overall Sentiment CNS Pharmaceuticals Neutral Neuphoria Therapeutics Neutral Is CNSP or NEUP more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CNS PharmaceuticalsN/A -385.41% -193.20% Neuphoria Therapeutics N/A N/A N/A Do insiders & institutionals have more ownership in CNSP or NEUP? 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 0.1% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer CNSP or NEUP? CNS Pharmaceuticals currently has a consensus target price of $300.00, indicating a potential upside of 3,796.10%. Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 160.87%. Given CNS Pharmaceuticals' higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, CNSP or NEUP? CNS Pharmaceuticals has higher earnings, but lower revenue than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00Neuphoria Therapeutics$10K1,513.40-$15.49MN/AN/A SummaryNeuphoria Therapeutics beats CNS Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.50M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.13%P/E Ratio0.0017.8528.9923.79Price / SalesN/A309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book0.128.488.255.54Net Income-$14.86M-$55.06M$3.25B$259.97M7 Day Performance-12.70%-3.99%-3.75%-4.67%1 Month Performance-30.33%8.53%2.99%3.29%1 Year Performance-94.88%6.51%25.34%17.92% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.0575 of 5 stars$7.70-3.5%$300.00+3,796.1%-94.9%$3.50MN/A0.005Gap DownNEUPNeuphoria Therapeutics1.2024 of 5 stars$8.69+2.2%$21.00+141.7%N/A$15.98M$10K0.00N/AMTEXMannatechN/A$8.05-3.4%N/A+24.5%$15.84M$117.87M-80.45250Gap DownALLRAllarity Therapeutics2.914 of 5 stars$1.12+9.8%$9.00+703.6%-79.1%$15.38MN/A0.0010Upcoming EarningsAnalyst DowngradeAnalyst RevisionGap DownHigh Trading VolumeLPTXLeap Therapeutics1.8817 of 5 stars$0.34-5.6%$3.38+893.8%-85.1%$14.91MN/A-0.2040Gap DownNERVMinerva Neurosciences2.7484 of 5 stars$2.10-1.4%$5.00+138.1%-33.6%$14.90MN/A2.569Positive NewsUpcoming EarningsGap UpEQEquillium1.8067 of 5 stars$0.45+10.7%$3.00+573.2%+2.7%$14.38M$30.41M-1.1440Upcoming EarningsGap UpERNAErnexa Therapeutics0.8531 of 5 stars$1.91-2.1%N/A-94.0%$14.36M$580K-0.2310BFRGBullfrog AI0.7923 of 5 stars$1.49-2.0%N/A-57.4%$14.31M$60K-1.844Upcoming EarningsALVRAlloVirN/A$2.76-2.8%N/A-84.8%$13.92MN/A-0.14110Upcoming EarningsHigh Trading VolumeBIVIBioVie0.1902 of 5 stars$7.10-5.1%N/A+67.5%$13.91MN/A-0.0910 Related Companies and Tools Related Companies NEUP Competitors MTEX Competitors ALLR Competitors LPTX Competitors NERV Competitors EQ Competitors ERNA Competitors BFRG Competitors ALVR Competitors BIVI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSP Stock Alerts